EP0833835A4 - Intermediaires de proteines contre l'obesite, leur preparation et leur utilisation - Google Patents

Intermediaires de proteines contre l'obesite, leur preparation et leur utilisation

Info

Publication number
EP0833835A4
EP0833835A4 EP96921702A EP96921702A EP0833835A4 EP 0833835 A4 EP0833835 A4 EP 0833835A4 EP 96921702 A EP96921702 A EP 96921702A EP 96921702 A EP96921702 A EP 96921702A EP 0833835 A4 EP0833835 A4 EP 0833835A4
Authority
EP
European Patent Office
Prior art keywords
preparation
obesity protein
protein intermediates
intermediates
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96921702A
Other languages
German (de)
English (en)
Other versions
EP0833835A1 (fr
Inventor
John Edward Hale
Warren Cameron Mackellar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0833835A1 publication Critical patent/EP0833835A1/fr
Publication of EP0833835A4 publication Critical patent/EP0833835A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J3/00—Working-up of proteins for foodstuffs
    • A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
    • A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP96921702A 1995-06-22 1996-06-20 Intermediaires de proteines contre l'obesite, leur preparation et leur utilisation Ceased EP0833835A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45195P 1995-06-22 1995-06-22
US451 1995-06-22
PCT/US1996/010613 WO1997000886A1 (fr) 1995-06-22 1996-06-20 Intermediaires de proteines contre l'obesite, leur preparation et leur utilisation

Publications (2)

Publication Number Publication Date
EP0833835A1 EP0833835A1 (fr) 1998-04-08
EP0833835A4 true EP0833835A4 (fr) 1999-05-26

Family

ID=21691591

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96921702A Ceased EP0833835A4 (fr) 1995-06-22 1996-06-20 Intermediaires de proteines contre l'obesite, leur preparation et leur utilisation

Country Status (5)

Country Link
EP (1) EP0833835A4 (fr)
JP (1) JPH11508134A (fr)
AU (1) AU6284896A (fr)
CA (1) CA2224867A1 (fr)
WO (1) WO1997000886A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2217698A1 (fr) * 1996-12-20 1998-06-20 Eli Lilly And Company Proteines contre l'obesite
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
DE10059336A1 (de) 2000-11-29 2002-06-13 Scil Proteins Gmbh Herstellung von rekombinantem BMP-2
ATE475094T1 (de) 2001-10-22 2010-08-15 Amgen Inc Verwendung von leptin zur behandlung von lipoatrophie im menschen und verfahren zur bestimmmung einer prädisposition gegenüber der behandlung
WO2010118384A2 (fr) 2009-04-10 2010-10-14 Amylin Pharmaceuticals, Inc. Composés agonistes de l'amyline pour mammifères ayant une carence en oestrogènes
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018227A2 (fr) * 1993-02-04 1994-08-18 Denzyme Aps Procede ameliore de repliement de proteines
WO1996005309A2 (fr) * 1994-08-17 1996-02-22 The Rockefeller University Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques
WO1996027385A1 (fr) * 1995-03-03 1996-09-12 Eli Lilly And Company Proteines contre l'obesite
WO1996034885A2 (fr) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Fragments peptidiques biologiquement actifs de proteines ob
WO1997006816A1 (fr) * 1995-08-17 1997-02-27 Amgen Inc. Procedes pour diminuer ou maintenir un niveau bas de lipides dans le sang, en utilisant des compositions de proteine ob

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018227A2 (fr) * 1993-02-04 1994-08-18 Denzyme Aps Procede ameliore de repliement de proteines
WO1996005309A2 (fr) * 1994-08-17 1996-02-22 The Rockefeller University Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques
WO1996027385A1 (fr) * 1995-03-03 1996-09-12 Eli Lilly And Company Proteines contre l'obesite
WO1996034885A2 (fr) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Fragments peptidiques biologiquement actifs de proteines ob
WO1997006816A1 (fr) * 1995-08-17 1997-02-27 Amgen Inc. Procedes pour diminuer ou maintenir un niveau bas de lipides dans le sang, en utilisant des compositions de proteine ob

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MURAKAMI T ET AL: "CLONING OF RAT OBESE CDNA AND ITS EXPRESSION IN OBESE RATS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 209, no. 3, 26 April 1995 (1995-04-26), pages 944 - 952, XP002003621 *
See also references of WO9700886A1 *

Also Published As

Publication number Publication date
CA2224867A1 (fr) 1997-01-09
AU6284896A (en) 1997-01-22
JPH11508134A (ja) 1999-07-21
WO1997000886A1 (fr) 1997-01-09
EP0833835A1 (fr) 1998-04-08

Similar Documents

Publication Publication Date Title
IL118469A (en) Naphthalene derivatives their preparation and intermediates thereof
IL126811A0 (en) Human b-cell antigens and related reagents
HU9601120D0 (en) Recombinant obese proteins
IL118237A0 (en) Polysiloxane-polyol macromers their preparation and their use
IL122215A0 (en) Dolastatin derivatives their preparation and use
IL118442A0 (en) Triazolymethyl-cyclopentanols their preparation and use
IL118441A0 (en) Triazolymethyl-oxiranes their preparation and use
AU6288296A (en) Novel human chemotactic cytokine
HUP9901343A3 (en) P53 protein variants and therapeutical uses thereof
GB9516059D0 (en) Novel genes and proteins
NZ300198A (en) Preparation of n-arylhydroxylamines and n-hetarylhydroxylamines
ZA96240B (en) Novel peptides their preparation and use
IL118295A0 (en) 3-(2- trialkylsilyloxy) ethyl-7-ethyl-1H- indoles and their preparation
AU4862396A (en) Human obesity gene
AU6284896A (en) Obesity protein intermediates and their preparation and use
ZA96239B (en) Novel peptides their preparation and use
GB9423372D0 (en) Proteins and their uses
IL131247A0 (en) Cash protein its preparation and use
HUP9801330A3 (en) Novel pka-binding proteins and uses thereof
AU4459196A (en) Sustained-release preparation and use
IL118444A0 (en) Mercapto-triazolyl-silanes their preparation and use
IL122686A0 (en) Benzylhydroxylamines their preparation and use
IL128746A0 (en) Ptx-sensitive g proteins their preparation and use
GB9519865D0 (en) Protein
IL118629A0 (en) N-Substituted cis-N-propenyl-acetemides their preparation and use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 971217;LT PAYMENT 971217;LV PAYMENT 971217;SI PAYMENT 971217

A4 Supplementary search report drawn up and despatched

Effective date: 19990409

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RHK1 Main classification (correction)

Ipc: C07K 14/575

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20000801

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1009819

Country of ref document: HK